Drug Development Lifecycle
Where Market Access & HEOR Sits in the Drug Development Journey
Preclinical & Phase I
Early safety signals
Phase II
Dose finding & efficacy
Phase III
Confirmatory trials
Regulatory Submission
NDA/BLA/MAA filing
Post-Marketing
Continuous surveillance
Market Access & HTA
Reimbursement & value
Key Challenges
Market Access & HEOR Challenges in Benefit-Risk Analysis
Securing reimbursement and market access requires navigating diverse HTA methodologies, generating country-specific evidence packages, and demonstrating value to payers with rigorous health economics analyses.
Country-Specific HTA Requirements
Each HTA body applies distinct methodological frameworks, evidence standards, and decision criteria. NICE requires reference-case cost-utility analysis with NHS perspective, G-BA demands AMNOG-compliant added benefit dossiers with specific comparator requirements, HAS applies its own SMR/ASMR rating system, and CADTH follows Canadian-specific pharmacoeconomic guidelines. Preparing separate submissions for each body is resource-intensive and error-prone when done manually, often requiring parallel workstreams with country-specific health economics teams.
QALY Modeling & Budget Impact Analysis
Constructing robust cost-effectiveness models requires synthesizing clinical trial data, real-world evidence, utility values, and country-specific cost inputs into Markov or partitioned survival models. Quality-adjusted life year (QALY) estimation demands validated utility mapping, appropriate discounting, and sensitivity analyses that withstand HTA committee scrutiny. Budget impact models must account for market uptake curves, treatment duration, displacement effects, and healthcare system-specific resource utilization patterns across multiple time horizons.
Comparative Effectiveness Evidence
HTA bodies increasingly require head-to-head comparative effectiveness data against locally relevant comparators. When direct trial evidence is unavailable, sponsors must conduct network meta-analyses (NMAs) or indirect treatment comparisons (ITCs) that meet each agency's methodological standards. Identifying the appropriate evidence network, assessing transitivity assumptions, and presenting results in agency-specific formats requires specialized expertise and significant analytical effort that compounds across multiple HTA submissions.
Real-World Evidence Generation for Payers
Payers and HTA bodies are placing growing emphasis on real-world evidence (RWE) to supplement clinical trial data. Generating credible RWE requires access to diverse data sources (claims databases, electronic health records, disease registries), sophisticated analytical methods to address confounding and selection bias, and transparent reporting that meets ISPE/ISPOR good practices. Integrating RWE into value dossiers demands careful contextualization alongside randomized controlled trial evidence to build a coherent value narrative for each market.
ArcaScience for Market Access & HEOR
How the Platform Addresses Market Access & HEOR Challenges
ArcaScience's three integrated modules provide end-to-end capabilities for health economics analysis, HTA submission preparation, and payer evidence generation.
Data Intelligence for Market Access
Access 100+ billion data points across claims databases, electronic health records, disease registries, and published HEOR literature to build robust evidence packages. Real-world evidence integration draws from country-specific data sources to support cost-effectiveness modeling, budget impact analysis, and comparative effectiveness research with locally relevant inputs.
- Country-specific RWE from EU5, US, and APAC data sources
- Utility value extraction from published EQ-5D and SF-36 studies
- Healthcare resource utilization data for budget impact modeling
Decision Intelligence for HEOR
Build cost-effectiveness models with automated QALY estimation, Markov state transition modeling, and partitioned survival analysis calibrated to each HTA body's reference case. Network meta-analysis capabilities synthesize comparative effectiveness evidence across disparate trial designs, generating forest plots and league tables formatted for HTA committee review.
- Automated cost-effectiveness and cost-utility modeling
- Network meta-analysis with agency-specific formatting
- Budget impact modeling with market uptake scenarios
Regulatory Outputs for Market Access
Generate submission-ready HTA dossiers, AMCP formulary dossiers, and payer evidence packages formatted to each agency's specific template and requirements. Automated report generation produces country-specific documents with locally relevant comparators, cost inputs, and clinical evidence summaries, reducing multi-market submission timelines by up to 60%.
- NICE technology appraisal submissions
- G-BA AMNOG benefit assessment dossiers
- AMCP formulary dossiers and payer value toolkits
Deliverables
Typical Outputs for Market Access & HEOR
ArcaScience generates submission-ready deliverables tailored to HTA body requirements and payer evidence needs across multiple markets.
HTA Dossiers
Country-specific HTA submission packages formatted for NICE, G-BA, HAS, CADTH, and other bodies, including clinical evidence summaries, economic evaluations, and budget impact analyses.
AMCP Formulary Dossiers
AMCP Format for Formulary Submissions compliant dossiers with clinical and economic evidence structured for US payer review and formulary placement decisions.
Budget Impact Models
Country-specific budget impact analyses with market uptake curves, treatment duration modeling, and displacement effects calibrated to local healthcare system resource utilization.
Comparative Effectiveness Reports
Network meta-analyses and indirect treatment comparisons with forest plots, league tables, and SUCRA rankings formatted for HTA committee presentations and payer negotiations.
Cost-Effectiveness Models
QALY-based cost-utility analyses with Markov state transition models, partitioned survival approaches, and probabilistic sensitivity analyses meeting HTA body reference-case specifications.
RWE Evidence Packages
Real-world evidence reports integrating claims data, registry data, and electronic health records to supplement clinical trial evidence for payer and HTA discussions.
Regulatory Context
What HTA Bodies Expect for Market Access
Understanding each HTA body's methodology, evidence requirements, and decision framework is essential for successful reimbursement and market access.
Market Access Case Study
EU5 HTA Submission Package for Rare Disease Therapy
A mid-size rare disease company faced the challenge of preparing simultaneous HTA submissions across all EU5 markets for a novel enzyme replacement therapy. Each country required distinct dossier formats, locally relevant comparators, country-specific cost inputs, and different economic modeling approaches. The traditional approach would require 5 separate HEOR consultancies working in parallel over 8–12 months.
ArcaScience's platform ingested the pivotal trial data, natural history registry evidence, and published utility values to generate 5 country-specific HTA dossiers from a single unified evidence base. The platform automatically adapted comparator analyses for each market (G-BA's designated appropriate comparator, NICE's relevant comparators, HAS's therapeutic positioning), applied country-specific cost inputs and discount rates, and produced formatted submissions meeting each agency's template requirements. The entire 5-country submission package was completed in 14 weeks.
Country-specific dossiers generated
Reduction in submission timeline
"Preparing 5 country-specific HTA dossiers simultaneously would normally require a team of 15+ health economists working for nearly a year. ArcaScience delivered all 5 submissions in 14 weeks from a single evidence base. The platform's ability to automatically adapt comparator analyses, cost inputs, and formatting for each HTA body transformed our market access strategy from sequential to simultaneous."
Dr. Elisabeth Hartmann
VP, Market Access & HEOR
Mid-size Rare Disease Company — Enzyme Replacement Therapies
Market access programs supported across EU5 & North America
Lifecycle Navigation
Explore Adjacent Development Phases
Previous Phase
Post-Marketing
Next Phase